MEDPHIGH SIGNALFINANCIAL10-K

MEDP reported strong revenue growth and improved profitability, but stockholders' equity declined significantly by 44% alongside reduced cash positions.

The substantial decline in stockholders' equity coupled with increased liabilities suggests either major capital deployment, significant shareholder returns, or potential balance sheet restructuring that warrants investor scrutiny. While operating performance appears robust with solid revenue expansion and margin improvement, the deteriorating equity position creates a disconnect between operational success and balance sheet health that requires explanation.

Comparing 2026-02-10 vs 2025-02-11View on EDGAR →
FINANCIAL ANALYSIS

MEDP delivered strong operational performance with revenue growing 20% to $2.5B and operating income expanding nearly 20% to $535M, while operating cash flow increased 17% to $713M. However, the balance sheet tells a concerning story with stockholders' equity declining 44% to $459M, cash positions falling 26% to $497M, and total liabilities rising 19% to $1.5B. The combination of strong earnings growth alongside significant equity deterioration suggests major capital allocation decisions or restructuring activities that fundamentally altered the company's financial structure.

FINANCIAL STATEMENT CHANGES
Stockholders Equity
Balance Sheet
-44.4%
$825.5M→$459.1M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Cash & Equivalents
Balance Sheet
-25.8%
$669.4M→$497.0M

Cash decreased 25.8% — monitor burn rate and upcoming capital needs.

Current Liabilities
Balance Sheet
+21.7%
$1.1B→$1.3B

Current liabilities rose 21.7% — increased short-term obligations, watch current ratio.

Revenue
P&L
+20%
$2.1B→$2.5B

Revenue growing 20% — solid top-line momentum, watch margins for quality of growth.

Operating Income
P&L
+19.7%
$446.9M→$534.9M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Total Liabilities
Balance Sheet
+18.9%
$1.3B→$1.5B

Liabilities increased 18.9% — monitor debt-to-equity ratio and interest coverage.

Operating Cash Flow
Cash Flow
+17.1%
$608.8M→$713.2M

Operating cash flow grew 17.1% — strong conversion of earnings to cash, healthy business fundamentals.

Net Income
P&L
+11.6%
$404.4M→$451.1M

Net income grew 11.6% — bottom-line growth signals improving overall business health.

LANGUAGE CHANGES
NEW — 2026-02-10
PRIOR — 2025-02-11
ADDED
Management's Discussion and Analysis of Financial Condition and Results of Operations 31 7A.
Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 76 9A.
As of December 31, 2024 and 2023, we had approximately 5,900 employees.
Approximately 66% of our employees globally are women representing 65% of management and 52% of director level and above positions.
based employees, approximately 17% are non-white, including 14% of management.
Of the 182 management-level roles that were newly filled between October 1, 2024 and September 30, 2025, approximately 75% of these roles were filled by our pipeline of internal talent.
In addition to physical security, we have programs and training in place for First Aid, CPR and Fire Wardens for safe evacuations.
Clinical trials can be costly and for the year ended December 31, 2025, 82% and 13% of our net revenue was derived from small biopharmaceutical companies and mid-sized biopharmaceutical companies, respectively, which may have limited access to capital.
These considerations might result in additional costs to us or otherwise adversely impact the progress of a clinical trial, our being unable to successfully achieve our projected development timelines, or potentially even lead to the termination of ongoing clinical trials or development of a product.
Despite any precautions we take, damage from fire, floods, hurricanes, power loss, telecommunications failures, computer viruses, information system intrusions or security breaches and similar events at our facilities or at those of our third party provider that backs up our data centers could result in interruptions in the flow of data to our servers and from our servers to our customers.
REMOVED
Management's Discussion and Analysis of Financial Condition and Results of Operations 32 7A.
Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 77 9A.
As of December 31, 2023 and 2022, we had approximately 5,900 and 5,200 employees, respectively.
Approximately 67% of our employees globally are women representing 66% of management and 53% of director level and above positions.
based employees, approximately 17% are non-white, including 13% of management.
Of the 153 management-level roles that were newly filled in 2024, approximately 67% of these roles were filled by our pipeline of internal talent.
We are proud of our extremely low incident rates and remain committed to continuously monitoring campus- and policy-related measures that can be incorporated in order to further reduce risk for our associates.
Clinical trials can be costly and for the year ended December 31, 2024, 79% and 17% of our net revenue was derived from small biopharmaceutical companies and mid-sized biopharmaceutical companies, respectively, which may have limited access to capital.
For example, if we are unable to engage investigators to conduct clinical trials as planned or enroll sufficient patients in clinical trials, we may need to expend additional funds to obtain access to resources or else be compelled to delay or modify the clinical trial plans.
The materialization of any of these risks may impede the processing of data, the delivery of databases and services and the day-to-day management of our business and could result in the corruption, loss or unauthorized disclosure of proprietary, confidential or other data.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →